Structural and defect chemistry guidelines for Sr(V,Nb)O3-based SOFC anode materials.
Structural and defect chemistry guidelines were used for Nb-substituted SrVO3-δ materials, designed to meet SOFC anode requirements, with emphasis on redox tolerance, thermochemical compatibility with other SOFC materials, electrical conductivity and adjustable changes in oxygen stoichiometry for their prospective impact on electrocatalytic performance. SrV1-xNbxO3-δ (x = 0-0.30) ceramics were prepared by solid-state synthesis and sintered at 1773 K in a reducing atmosphere. XRD and SEM/EDS showed that under these conditions a single-phase cubic perovskite structure appears up to x ≈ 0.25. Electrical conductivity is metallic-like and nearly p(O2)-independent. Although substitution by niobium decreases the conductivity, which still exceeds 100 S cm(-1) for x ≤ 0.20 at temperatures below 1273 K, it also expands the stability domain of the cubic perovskite phase and suppresses partly high thermochemical expansion characteristic of parent SrVO3-δ. The upper p(O2) limit of phase stability was found to shift from ∼2 × 10(-15) atm for the undoped material to ∼2 × 10(-12) atm for x = 0.30, whereas the average thermal expansion coefficient at 773-1223 K decreased from 22.7 × 10(-6) to 13.3 × 10(-6) K(-1). SrV1-xNbxO3-δ perovskites undergo oxidative decomposition in air, which causes dimensional and microstructural changes. However, sluggish kinetics of oxidation under inert gas conditions results in nearly reversible behavior in relatively short-term redox cycles between reducing and inert atmospheres. Subtle structural changes and a close correlation with point defect chemistry clarify these sluggish changes and provide guidelines to retain the metastability.
Studies on the solid solutions of Ln1−xSrxVO3−0.1x
Abstract Solid solutions (Ln 1−x Sr x VO 3−0.1x ; Ln:La, Nd, Eu, Gd, Er or Yb) composed with rare-earth vanadites (LnVO 3 ) and strontium vanadite (SrVO 2.9 ) and resulted from the reaction of Ln 2 O 3 , V 2 O 3 and SrO were studied. If the value of x in Ln 1−x Sr x VO 3−0.1x was lower than a certain value, crystals isostructural with LnVO 3 (Ln:La, tetragonal cell; Ln:Nd, Eu or Gd, orthorhombic cell) were obtained; if the value of x was higher than that, the products belonging to a cubic system isomorphous with SrVO 2.9 , were formed in the case of La, Nd, Eu or Gd. As the ionic radius of the incorporated rare-earth ion becomes larger, the region of the cubic-phase formation increases in size.
Improved Skin Penetration Using In Situ Nanoparticulate Diclofenac Diethylamine in Hydrogel Systems: In Vitro and In Vivo Studies
Delivering diclofenac diethylamine transdermally by means of a hydrogel is an approach to reduce or avoid systemic toxicity of the drug while providing local action for a prolonged period. In the present investigation, a process was developed to produce nanosize particles (about 10 nm) of diclofenac diethylamine in situ during the development of hydrogel, using simple mixing technique. Hydrogel was developed with polyvinyl alcohol (PVA) (5.8% w/w) and carbopol 71G (1.5% w/w). The formulations were evaluated on the basis of field emission scanning electron microscopy, texture analysis, and the assessment of various physiochemical properties. Viscosity (163–165 cps for hydrogel containing microsize drug particles and 171–173 cps for hydrogel containing nanosize drug particles, respectively) and swelling index (varied between 0.62 and 0.68) data favor the hydrogels for satisfactory topical applications. The measured hardness of the different hydrogels was uniform indicating a uniform spreadability. Data of in vitro skin (cadaver) permeation for 10 h showed that the enhancement ratios of the flux of the formulation containing nanosize drug (without the permeation enhancer) were 9.72 and 1.30 compared to the formulation containing microsized drug and the marketed formulations, respectively. In vivo plasma level of the drug increased predominantly for the hydrogel containing nanosize drug-clusters. The study depicts a simple technique for preparing hydrogel containing nanosize diclofenac diethylamine particles in situ, which can be commercially viable. The study also shows the advantage of the experimental transdermal hydrogel with nanosize drug particles over the hydrogel with microsize drug particles.